A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.
HDP-102-01
Phase 1 other active
Quick answer
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. for Relapsed/Refractory B-cell Malignancies is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Relapsed/Refractory B-cell Malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active